One more fact you keep omitting: the company has already stated it cannot release additional patient-level data until the treating facility completes and submits its peer-reviewed publication.
That’s not secrecy — that’s standard clinical ethics and publication protocol. Trial sites control data release, not sponsors, especially in early human studies.
So the absence of rolling updates isn’t “hiding results.” It’s respecting the study site, the investigators, and the peer-review process.
If the data were meaningless, there wouldn’t be a manuscript in preparation — and regulators wouldn’t still be engaged at all.
Silence under publication rules doesn’t = failure.
It means the process is being done correctly.
Market Data 
Markets 
AI
